Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 1/20 | 0.58 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.58 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.57 |
| ▸ | HRH2 | P25021 | 4/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2755855 | 0.90 | QPCT (0.71) | QPCTQPCTLHRH4HRH2HRH3 | |
| SCHEMBL19059415 | 0.82 | CYP3A4 (0.54) | QPCTQPCTLHRH4HRH2HRH3 | |
| SCHEMBL19059737 | 0.81 | CYP3A4 (0.60) | HRH4HRH2HRH3CYP3A4CYP2D6 | |
| SCHEMBL19059656 | 0.79 | CYP3A4 (0.54) | QPCTQPCTLHRH4HRH3CYP3A4 | |
| SCHEMBL28530363 | 0.76 | CYP3A4 (0.71) | QPCTQPCTLHRH4HRH3CYP3A4 | |
| SCHEMBL17483161 | 0.76 | QPCT (0.75) | QPCTQPCTLHRH4HRH3CYP3A4 | |
| SCHEMBL21858082 | 0.76 | QPCT (0.75) | QPCTQPCTLHRH4HRH3CYP3A4 | |
| SCHEMBL18381442 | 0.76 | CYP3A4 (0.74) | QPCTQPCTLHRH4HRH2HRH3 | |
| SCHEMBL18381410 | 0.76 | CYP3A4 (0.74) | HRH4HRH2HRH3CYP3A4CYP2D6 | |
| SCHEMBL11036080 | 0.75 | HRH4 (0.86) | HRH4HRH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223755-B2 | Hydroxymorpholinone derivative and medicinal use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2007-05-29 | — | — | US | disclosed |
| US-20050176704-A1 | Hydroxymorpholinone derivative and medicinal use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176704-A1 | Hydroxymorpholinone derivative and medicinal use thereof | CAPN1, OPRM1, CAPN2 | QPCT 4475/4885QPCTL 4432/4885HRH4 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.